Research programme: stem cell therapies - RaQualia/IPS Academia Japan/ Kyoto UniversityAlternative Names: Induced pluripotent stem cells - RaQualia; iPS cells - RaQualia
Latest Information Update: 22 May 2014
At a glance
- Originator iPS Academia Japan; Kyoto University; RaQualia Pharma
- Class Stem cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 15 May 2014 Early research in Undefined indication in Japan (unspecified route)